- X4 Pharmaceuticals will hold its annual meeting virtually on May 11, 2026.
- Shareholders will vote to elect three Class III director nominees to serve until the 2029 annual meeting.
- The meeting agenda also includes ratifying PricewaterhouseCoopers as independent auditor for the year ending December 31, 2026.
- Items up for approval include a 1.5 million-share increase under the Second Amended and Restated 2017 Equity Incentive Plan.
- A non-binding advisory vote on named executive officer compensation is also scheduled.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. X4 Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001501697-26-000031), on March 20, 2026, and is solely responsible for the information contained therein.
Comments